Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in recent-onset type 1 diabetes
ACTRN12617000016336Phase 2Completed
- Sponsor
- Melbourne Health
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of empagliflozin in diabetes mellitus type 1 (T1D), sponsored by Melbourne Health. Primary endpoint: Protocol compliance. Started Mar 2017; status: completed.
02
Drugs
empagliflozin
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ACTRN12617000016336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000016336.